Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IICompletedAug 30, 2023AstrinGynCGMP Deviations: Products not manufactured under current good manufacturing practices.Ecometics, Inc. · D-1101-2023Class IICompletedAug 30, 2023activator concentrateCGMP Deviations: Products not manufactured under current good manufacturing practices.Ecometics, Inc. · D-1100-2023Class IICompletedAug 30, 2023Unguentine OintmentCGMP Deviations: Products not manufactured under current good manufacturing practices.Ecometics, Inc. · D-1099-2023Class IICompletedAug 30, 2023ALCOLADO RELAMPAGOCGMP Deviations: Products not manufactured under current good manufacturing practices.Ecometics, Inc. · D-1098-2023Class IICompletedAug 30, 2023YAGER'S LINIMENTCGMP Deviations: Products not manufactured under current good manufacturing practices.Ecometics, Inc. · D-1097-2023Class IICompletedAug 30, 2023Blis-To-Sol LiquidCGMP Deviations: Products not manufactured under current good manufacturing practices.Ecometics, Inc. · D-1096-2023Class IIIOngoingAug 30, 2023Trandolapril and Verapamil Hydrochloride Extended-Release Tablets 2 mg / 180 mgSubpotent: Out of Specification for Assay Test at the 3-month time point.Glenmark Pharmaceuticals Inc., USA · D-1095-2023Class IIITerminatedAug 30, 2023Moxifloxacin - Bromfenac Sterile Ophthalmic Solution 0.5% / 0.075%Subpotent Drug; sub-potent Bromfenac levels, below the 90.0-110.0% specification range.Imprimis NJOF, LLC · D-1094-2023Class IITerminatedAug 30, 2023Helix CBD Clinical CreamCGMP DeviationsParker Laboratories, Inc. · D-1093-2023Class IITerminatedAug 30, 2023Helix CBD Therapy CreamCGMP DeviationsParker Laboratories, Inc. · D-1092-2023Class IITerminatedAug 30, 2023Helix Tri-Active Therapy CreamCGMP DeviationsParker Laboratories, Inc. · D-1091-2023Class IITerminatedAug 30, 2023Helix Pain Relieving CreamCGMP DeviationsParker Laboratories, Inc. · D-1090-2023Class IITerminatedAug 30, 2023Protex Foaming Hand SanitizerCGMP DeviationsParker Laboratories, Inc. · D-1089-2023Class IITerminatedAug 30, 2023Rufinamide TabletscGMP deviations: Batch was released prior to approval.Aurobindo Pharma USA Inc. · D-1088-2023Class IITerminatedAug 30, 2023Rufinamide TabletscGMP deviations: Batch was released prior to approval.Aurobindo Pharma USA Inc. · D-1087-2023Class IIIOngoingAug 23, 2023Tobramycin Opthalmic Solution USPFailed Impurities/Degradation SpecificationsAlembic Pharmaceuticals, Inc. · D-1086-2023Class IIITerminatedAug 23, 2023PLUVICTO 1Labeling: Incorrect or Missing Lot and/or Exp Date: vials were labeled with the incorrect lot number and expiration dateAdvanced Accelerator Applications USA, Inc. · D-1085-2023Class IITerminatedAug 23, 2023hello wild strawberry fluoride toothpasteLabeling: Label Mix-Up: Some hello wild strawberry fluoride toothpaste, packaged in cartons labeled as hello wild strawberry fluoride toothpaste were incorrectly filled...Colgate Palmolive Company · D-1084-2023Class IIITerminatedAug 16, 20230.9% Sodium Chloride Injection USPLabeling: Not Elsewhere Classified - the description, warnings, storage information and instructions for use are either missing or partially printed.B. Braun Medical Inc. · D-1083-2023Class IIITerminatedAug 16, 2023Dofetilide Capsules 500 mcgOut of Specification result observed in content uniformity testingSun Pharmaceutical Industries Inc · D-1082-2023Class ITerminatedAug 9, 2023Tydemy (drospirenoneFailed Stability Specification and Failed Impurities/Degradation Specifications: out of specification for inactive content ascorbic acid and MTHFRC-7impurity testLupin Pharmaceuticals Inc. · D-1081-2023Class IITerminatedAug 9, 2023morphine in 0.9% Sodium ChlorideLack of assurance of sterility: Lack of validation data for sanitization cyclesCentral Admixture Pharmacy Services Inc · D-1080-2023Class IITerminatedAug 9, 2023fentaNYL in 0.9% sodium chlorideLack of assurance of sterility: Lack of validation data for sanitization cyclesCentral Admixture Pharmacy Services Inc · D-1079-2023Class IITerminatedAug 9, 2023PHENYLephrine in 0.9 sodium chlorideLack of assurance of sterility: Lack of validation data for sanitization cyclesCentral Admixture Pharmacy Services Inc · D-1078-2023Class IITerminatedAug 9, 2023PHENYLephrine in 0.9 sodium chlorideLack of assurance of sterility: Lack of validation data for sanitization cyclesCentral Admixture Pharmacy Services Inc · D-1077-2023Class IITerminatedAug 9, 2023rocuroniumLack of assurance of sterility: Lack of validation data for sanitization cyclesCentral Admixture Pharmacy Services Inc · D-1076-2023Class IITerminatedAug 9, 2023midazolam in dextrose 5%Lack of assurance of sterility: Lack of validation data for sanitization cyclesCentral Admixture Pharmacy Services Inc · D-1075-2023Class IITerminatedAug 9, 2023lidocaine 2%Lack of assurance of sterility: Lack of validation data for sanitization cyclesCentral Admixture Pharmacy Services Inc · D-1074-2023Class IITerminatedAug 9, 2023ePHEDrine in 0.9% sodium chlorideLack of assurance of sterility: Lack of validation data for sanitization cyclesCentral Admixture Pharmacy Services Inc · D-1073-2023Class IITerminatedAug 9, 2023fentaNYL 2 mcg/mL and bupivacaine 0.125% PF in 0.9% sodium chloride / Total Volume = 250 mLLack of assurance of sterility: Lack of validation data for sanitization cyclesCentral Admixture Pharmacy Services Inc · D-1072-2023Class IITerminatedAug 9, 2023ketamine in 0.9% sodium chlorideLack of assurance of sterility: Lack of validation data for sanitization cyclesCentral Admixture Pharmacy Services Inc · D-1071-2023Class IITerminatedAug 9, 2023fentaNYL 2 mcg/mL and bupivacaine 0.125% PF in 0.9% sodium chlorideLack of assurance of sterility: Lack of validation data for sanitization cyclesCentral Admixture Pharmacy Services Inc · D-1070-2023Class IITerminatedAug 9, 2023fentaNYL 2 mcg/mL and bupivacaine 0.0625% PF in 0.9% sodium chlorideLack of assurance of sterility: Lack of validation data for sanitization cyclesCentral Admixture Pharmacy Services Inc · D-1069-2023Class IITerminatedAug 9, 2023morphine in 0.9% sodium chlorideLack of assurance of sterility: Lack of validation data for sanitization cyclesCentral Admixture Pharmacy Services Inc · D-1068-2023Class IITerminatedAug 9, 2023fentaNYL 1.5 mcg/mL and bupivacaine 0.125% PF in 0.9% sodium chlorideLack of assurance of sterility: Lack of validation data for sanitization cyclesCentral Admixture Pharmacy Services Inc · D-1067-2023Class IITerminatedAug 9, 2023PHENYLephrine in 0.9% sodium chlorideLack of assurance of sterility: Lack of validation data for sanitization cyclesCentral Admixture Pharmacy Services Inc · D-1066-2023Class IITerminatedAug 9, 2023morphine in 0.9% sodium chlorideLack of assurance of sterility: Lack of validation data for sanitization cyclesCentral Admixture Pharmacy Services Inc · D-1065-2023Class IITerminatedAug 9, 2023morphine in 0.9% sodium chlorideLack of assurance of sterility: Lack of validation data for sanitization cyclesCentral Admixture Pharmacy Services Inc · D-1064-2023Class IITerminatedAug 9, 2023fentaNYL in 0.9% sodium chlorideLack of assurance of sterility: Lack of validation data for sanitization cyclesCentral Admixture Pharmacy Services Inc · D-1063-2023Class IITerminatedAug 9, 2023fentaNYL in 0.9% sodium chlorideLack of assurance of sterility: Lack of validation data for sanitization cyclesCentral Admixture Pharmacy Services Inc · D-1062-2023